Showing results (231-240 of 255) with videos related to
Sort By:
Pageof 26
Blood|September 10, 2024
Real-world impact of differences in the WHO and ICC classifications of non-Hodgkin lymphoma: a LEO cohort study analysisBrooj Abro, Matthew J Maurer, Thomas M Habermann, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 13, 2016
US Intergroup Trial of Response-Adapted Therapy for Stage III to IV Hodgkin Lymphoma Using Early Interim Fluorodeoxyglucose-Positron Emission Tomography Imaging: Southwest Oncology Group S0816Oliver W Press, Hongli Li, Heiko Schöder, et al.Leukemia|February 19, 2026
Repression of miR-29 via MYC leads to increased CD40 signaling in transformed follicular lymphomaDaniel Filip, Katerina Litzmanova, Androniki Michaelou, et al.The New England Journal of Medicine|December 14, 2021
Polatuzumab Vedotin in Previously Untreated Diffuse Large B-Cell LymphomaHervé Tilly, Franck Morschhauser, Laurie H Sehn, et al.Blood|May 31, 2024
Randomized study of induction with bendamustine-rituximab ± bortezomib and maintenance with rituximab ± lenalidomide for MCLMitchell R Smith, Opeyemi A Jegede, Peter Martin, et al.Blood|September 25, 2025
PROs vs clinician-reported adverse events in a large clinical trial: findings from the phase 3 POLARIX studyCarrie Thompson, Marek Trněný, Franck Morschhauser, et al.Blood Advances|February 18, 2026
Patterns of Care and Clinical Outcomes in Systemic Peripheral T-cell Lymphoma: The LEO-MER Prospective Cohort StudyJia Ruan, Zhengming Chen, Melissa C Larson, et al.American Journal of Hematology|June 6, 2015
Gray zone lymphoma with features intermediate between classical Hodgkin lymphoma and diffuse large B-cell lymphoma: characteristics, outcomes, and prognostication among a large multicenter cohortAndrew M Evens, Jennifer A Kanakry, Laurie H Sehn, et al.Blood|July 27, 2016
Brentuximab vedotin and AVD followed by involved-site radiotherapy in early stage, unfavorable risk Hodgkin lymphomaAnita Kumar, Carla Casulo, Joachim Yahalom, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|April 3, 2019
Dose-Adjusted EPOCH-R Compared With R-CHOP as Frontline Therapy for Diffuse Large B-Cell Lymphoma: Clinical Outcomes of the Phase III Intergroup Trial Alliance/CALGB 50303Nancy L Bartlett, Wyndham H Wilson, Sin-Ho Jung, et al.Pageof 26